A bold reframe: a common water pill, spironolactone, might become a valuable addition to HIV treatment beyond standard antiretroviral therapy.
New findings from the Valente lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology show that spironolactone, typically prescribed as a diuretic for heart and blood pressure conditions, could play a supportive role in HIV management. Viruses hijack a cell’s transcription machinery to replicate. Current HIV meds control the virus but do not cure it; when treatment stops, the virus can rebound from hidden reservoirs. This study explored whether a long-acting form of spironolactone, used alongside first‑line antiretroviral therapy, could enhance viral control.
In experiments with HIV-infected mice repopulated with human immune cells, researchers compared standard antiretroviral therapy alone to therapy plus spironolactone. The combination accelerated the drop of HIV in the blood and reduced tissue inflammation, without decreasing immune cell counts or diminishing the latent HIV DNA that persists in cells. Co-corresponding author Susana T. Valente, Ph.D., notes that the approach aims to “block and lock” the virus: block its gene copying and push it into a durable dormant state.
The study, published online November 30 in Emerging Microbes & Infections, reported a 4.4-fold reduction in HIV RNA within cells across the body when spironolactone was added. Inflammation-related gene activity also fell broadly. Importantly, the amount of proviral DNA remained unchanged, indicating spironolactone quiets viral activity rather than eradicating infected cells.
Spironolactone is known for a long safety record and works by blocking aldosterone, a hormone involved in salt and water balance. In this research, spironolactone appeared to suppress HIV gene activity through an additional mechanism, helping the virus enter or maintain a dormant state.
Valente emphasizes the potential benefits: even with today’s effective antiretroviral therapy, small amounts of viral activity can persist and contribute to inflammation and related health issues. An affordable add‑on that further quiets the virus could improve long‑term outcomes.
The researchers caution that further work is needed. Next steps include preclinical studies to optimize dosing and timing, and combining spironolactone with other agents that suppress viral activity to assess durability, safety, and drug interactions before any clinical testing.
Valente concludes that these findings justify exploring transcriptional inhibitors like spironolactone as adjuncts to antiretroviral therapy, aiming to speed up viral suppression and lessen chronic inflammation.
Source:
Journal reference:
